Q-omics provides the consensus-scored FUT11 profile across patient tissues and cancer cell-line models. FUT11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FUT11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FUT11 protein abundance shows 20,568 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where FUT11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUT11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUT11 survival associations across molecular data types. FUT11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUT11 RNA expression–survival associations across cancer types. High FUT11 expression shows unfavorable associations in UVM, CESC, ACC, BLCA and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FUT11 RNA expression.
This table summarizes FUT11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FUT11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUT11 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, KIRP and LIHC. The KIRC box plot shows higher FUT11 RNA expression in tumor versus normal tissue (log2 FC = +1.788, t-test p < 0.001).
This table shows molecular features associated with FUT11 in patient tissues and cancer cell lines. In patient samples, FUT11 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FUT11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
